AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a report issued on Friday, AnalystRatings.com reports.
AMAG has been the subject of a number of other research reports. Piper Jaffray Companies reissued a “neutral” rating and issued a $9.00 price target on shares of AMAG Pharmaceuticals in a report on Wednesday, August 7th. ValuEngine lowered shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, August 8th. Finally, BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $14.69.
AMAG stock opened at $12.26 on Friday. AMAG Pharmaceuticals has a twelve month low of $6.81 and a twelve month high of $22.79. The business’s 50-day simple moving average is $11.77 and its 200 day simple moving average is $10.64. The company has a quick ratio of 1.50, a current ratio of 1.60 and a debt-to-equity ratio of 0.55. The company has a market cap of $365.21 million, a PE ratio of -3.16 and a beta of 0.39.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.62). The firm had revenue of $78.00 million during the quarter, compared to the consensus estimate of $90.72 million. AMAG Pharmaceuticals had a negative net margin of 64.33% and a negative return on equity of 31.31%. The business’s revenue was down 46.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.75) EPS. On average, equities research analysts anticipate that AMAG Pharmaceuticals will post -2.94 EPS for the current year.
In other AMAG Pharmaceuticals news, major shareholder Armistice Capital, Llc bought 260,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was purchased at an average price of $7.32 per share, with a total value of $1,903,200.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Camber Capital Management Lp bought 385,000 shares of the stock in a transaction on Friday, August 9th. The shares were acquired at an average cost of $7.87 per share, with a total value of $3,029,950.00. The disclosure for this purchase can be found here. Company insiders own 4.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMAG. Nuveen Asset Management LLC acquired a new stake in AMAG Pharmaceuticals during the 2nd quarter worth $6,911,000. Camber Capital Management LP grew its holdings in AMAG Pharmaceuticals by 13.2% during the 2nd quarter. Camber Capital Management LP now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $29,970,000 after acquiring an additional 350,000 shares during the period. Acadian Asset Management LLC grew its holdings in AMAG Pharmaceuticals by 34.7% during the 2nd quarter. Acadian Asset Management LLC now owns 919,064 shares of the specialty pharmaceutical company’s stock worth $9,180,000 after acquiring an additional 236,984 shares during the period. Permanens Capital L.P. grew its holdings in AMAG Pharmaceuticals by 319.7% during the 2nd quarter. Permanens Capital L.P. now owns 266,500 shares of the specialty pharmaceutical company’s stock worth $2,662,000 after acquiring an additional 203,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in AMAG Pharmaceuticals by 66.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 447,715 shares of the specialty pharmaceutical company’s stock worth $4,473,000 after acquiring an additional 179,310 shares during the period.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.